Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI -1.58%54 EV-to-Revenue is 0.04 as of Aug. 31, 2026, which is 92% below its 10-year median of 0.51. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.82 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 962 Drug Manufacturers companies, Euroapi ranks better than 97.61% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Euroapi's enterprise value is €35.0 Mil.
Euroapi's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €852.6 Mil. Therefore, Euroapi's EV-to-Revenue for today is 0.04.
The historical rank and industry rank for Euroapi's EV-to-Revenue or its related term are showing as below:
XPAR:EAPI'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.04 Med: 0.51 Max: 1.97
Current: 0.04
During the past 7 years, the highest EV-to-Revenue of Euroapi was 1.97. The lowest was 0.04. And the median was 0.51.
XPAR:EAPI's EV-to-Revenue is ranked better than 97.61% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.495
vs XPAR:EAPI: 0.04
As of today (2026-08-31), Euroapi's stock price is €0.932.
Euroapi's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €8.98. Therefore, Euroapi's PS Ratio for today is 0.10.
Euroapi's share price for today is €0.932.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was €8.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroapi EV-to-Revenue Related Terms
Euroapi EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Euroapi's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:EAPI vs ZTS, UTHR, VTRS: EV-to-Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi EV-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Euroapi's EV-to-Revenue falls into.
Euroapi's current Enterprise Value is €35.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Euroapi's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €852.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroapi (XPAR:EAPI) has a EV-to-Revenue of 0.04 as of Aug. 31, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Euroapi and its competitors. This is 92% below median its historical median of 0.51. Over the past decade, Euroapi's EV-to-Revenue has ranged from 0.04 to 1.97. According to the industry distribution chart, Euroapi ranks #23 out of 962 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Euroapi's EV-to-Revenue too high?
Euroapi's current EV-to-Revenue of 0.04 is 92% below median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.97. The Drug Manufacturers industry median EV-to-Revenue is 2.50. Euroapi's value of 0.04 is 98.4% below this industry median. Based on the distribution chart, Euroapi ranks #23 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's EV-to-Revenue compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #23 out of 962 companies for EV-to-Revenue. This places Euroapi in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 2.50. Euroapi's value of 0.04 is 98.4% below this benchmark. Historically, Euroapi's own EV-to-Revenue has ranged from 0.04 to 1.97 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 2.50, Euroapi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Drug Manufacturers company?
The median EV-to-Revenue among Drug Manufacturers companies is 2.50, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euroapi's current EV-to-Revenue of 0.04 is 98.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median EV-to-Revenue is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current EV-to-Revenue is 0.04, which is 92% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.82, compared to a current price of €0.93 — trading 67% below its estimated fair value. The current EV-to-Revenue is 0.04, which is 92% below median its 10-year median of 0.51 and 98.4% below the Drug Manufacturers industry median of 2.50. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current EV-to-Revenue is 0.04 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €0.93 is trading 67% below its estimated GF Value™ of €2.82.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
EV-to-Revenue: 0.04 (92% below median its 10-year median of 0.51)
GF Value™: €2.82 vs. price of €0.93 (67% below fair value)
Industry Position: 98.4% below the Drug Manufacturers median (#23 of 962)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score
Get the complete analysis for XPAR:EAPI
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
